Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Kiniksa is shifting to next-gen IL-1 antibodies for recurrent pericarditis. Click here to read more on how this impacts KNSA stock in 2025 and beyond.

Kiniksa Pharmaceuticals International reported significant financial results for Q4 and full year 2024, with ARCALYST® (rilonacept) net product revenues reaching $122.5 million for Q4 and $417 ...

Kiniksa Pharmaceuticals International, plc's Arcalyst is gaining traction with significant revenue growth, driven by its unique position as the only approved drug for recurrent pericarditis.

We recently compiled a list of the 12 Best Small Cap Pharma Stocks to Buy Now. In this article, we are going to take a look ...

Kiniksa Pharmaceuticals (KNSA) witnessed a jump in share price last session on above-average trading volume. The latest trend ...

Kiniksa (KNSA) expects 2025 ARCALYST net product revenue of between $560 million and $580 million. Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.

ARCALYST ® (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively – – ARCALYST 2025 net product revenue expected to be $560 - $580 ...

Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances ...

Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL-387 Phase 2/3 clinical ...